June 26, 2025 — Stepping back from the intense swirl of obesity care research at the ADA meeting just concluded, one thing stands out: People are having a very hard time following the thread of all this innovation. If you have any doubt, just scan the reports of investment analysts at the meeting. On one hand, they know they […]
June 19, 2025 — In drug therapy for obesity, all of the excitement about GLP-1s and now amylin analogs has focused on regulation of eating behaviors. But, in fact, this is just one part of the process for regulating metabolic function and adiposity. Until now, we have seen little success in developing safe and effective medicines that alter the […]
June 14, 2025 — As the upcoming Scientific Sessions for the American Diabetes Association draws closer, the drumbeat for amycretin as a promising new therapy for obesity is growing louder. At the meeting, Novo Nordisk plans to present two different studies to strengthen the case for this novel dual agonist. It targets both GLP-1 and amylin receptors. Then yesterday […]
May 3, 2025 — Rather quietly this week, Eli Lilly and Company announced that it had withdrawn an application to FDA for an indication to use tirzepatide (Zepbound) in treating heart failure – specifically for HFpEF. This news came up in a briefing for investors, with Lilly’s Chief Scientific Officer, Dan Skovronsky, saying: “Following discussions with the FDA, we’ve […]
April 18, 2025 — The news in obesity research these days is so full of headlines about a multitude of new medicines in development that it is easy to lose count. All too often, these are early stage or even pre-clinical notions of a potential treatment. So yesterday, it was good news indeed to hear that a once-daily oral […]
March 11, 2025 — Drug development is tricky. If you want evidence for just how tricky it is, a quick look at the experience with CagriSema will give you a pretty good idea. Yesterday, Novo Nordisk announced topline results of this drug from their REDEFINE 2 clinical trial. Their press release talked about “superior results” for people with overweight […]
February 27, 2025 — More than a decade ago, targeting amylin receptors for treating obesity looked like hot opportunity. Amylin, a peptide hormone co-secreted with insulin by pancreatic beta cells, plays a role in regulating satiety and food intake. An amylin analog, pramlintide, gained FDA approval for treating diabetes. But efforts to develop it for treating obesity never quite […]
January 25, 2025 — The race to innovate beyond semaglutide and tirzepatide for obesity can be utterly confusing. More than a hundred new drugs are in various stages of development and analysts expect more than a dozen to be launched within the next five years. But right now, all we have are tantalizing – and sometimes disappointing – results […]
January 8, 2025 — Drug development for obesity may well be in a golden age. In large part, this is because the scientific understanding of obesity has grown exponentially in the past two decades. Unfortunately, little or none of that is reflected in new draft guidance from FDA, issued yesterday for public comment, on developing the next generation of […]
November 27, 2024 — Yesterday, Amgen released topline data on their remarkable monthly obesity medicine – MariTide or maridebart cafraglutide. To us, the results are impressive, albeit preliminary. In 52 weeks of study, patients with obesity or overweight lost approximately 20% of their initial body weight and even after a year, they appeared to still be losing weight. For […]
